Raffi Asadorian is CFO at ACELRX PHARMACEUTICALS INC (ACRX). They have made 9 open-market trades across 2 companies since 2017, most recently 2026-04-02.
CIK 0001628970
8 open-market purchases totalling $138K since 2017, against 1 sale. Across 8 scored buys the stock is down 7.7% at ninety days, and 11.2 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| TLPH | 85,879 | $93K |
| ACRX | 22,081 | $19K |
| AMRS | 241,648 | $12K |
| Total | $124K |
Shares reported on the most recent Form 4, priced at the 2026-04-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 63% | 38% | 25% |
| Avg Move | +1.5% | +4.4% | -7.7% |
| Alpha | +1.8% | +4.0% | -11.2% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TLPH | BUY | 2026-02-12 | 2026-02-20 | $0.81 | $36K | +5.8% | -7.0% | -5.3% |
| TLPH | SELL | 2024-12-02 | 2024-12-02 | $0.77 | $119 | -13.5% | -22.4% | -28.9% |
| ACRX | BUY | 2019-02-28 | 2019-03-04 | $2.81 | $10K | -22.1% | -11.6% | -37.0% |
| ACRX | BUY | 2018-12-14 | 2018-12-17 | $2.78 | $14K | -14.9% | -14.5% | +15.3% |
| ACRX | BUY | 2018-11-13 | 2018-11-13 | $3.13 | $16K | +17.8% | -8.6% | -20.1% |
| ACRX | BUY | 2018-08-06 | 2018-08-06 | $2.75 | $14K | +6.9% | +12.1% | +47.2% |
| ACRX | BUY | 2018-05-25 | 2018-05-29 | $3.18 | $16K | +8.8% | +2.9% | -13.2% |
| ACRX | BUY | 2017-11-13 | 2017-11-14 | $1.94 | $10K | +12.8% | +0.0% | -12.8% |
| ACRX | BUY | 2017-09-11 | 2017-09-11 | $3.24 | $23K | -3.0% | +62.1% | -35.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.